Aclaris Therapeutics (ACRS) EPS (Weighted Average and Diluted): 2019-2025
Historic EPS (Weighted Average and Diluted) for Aclaris Therapeutics (ACRS) over the last 5 years, with Sep 2025 value amounting to -$0.12.
- Aclaris Therapeutics' EPS (Weighted Average and Diluted) fell 9.09% to -$0.12 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.58, marking a year-over-year decrease of 203.85%. This contributed to the annual value of -$1.71 for FY2024, which is 34.65% down from last year.
- Per Aclaris Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.12 for Q3 2025, which was up 7.69% from -$0.13 recorded in Q2 2025.
- Over the past 5 years, Aclaris Therapeutics' EPS (Weighted Average and Diluted) peaked at -$0.02 during Q4 2023, and registered a low of -$1.21 during Q4 2024.
- Over the past 3 years, Aclaris Therapeutics' median EPS (Weighted Average and Diluted) value was -$0.15 (recorded in 2024), while the average stood at -$0.30.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first skyrocketed by 95.12% in 2023, then tumbled by 5,950.00% in 2024.
- Quarterly analysis of 5 years shows Aclaris Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.37 in 2021, then decreased by 10.81% to -$0.41 in 2022, then surged by 95.12% to -$0.02 in 2023, then plummeted by 5,950.00% to -$1.21 in 2024, then dropped by 9.09% to -$0.12 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.12 in Q3 2025, compared to -$0.13 in Q2 2025 and -$0.12 in Q1 2025.